Title: Comparative Real-world Outcomes between Ustekinumab, Infliximab, and Adalimumab
in Bio-naïve and Bio-experienced Crohn’s Disease Patients: A Retrospective Multicenter Study
Version: 4 Date: 10 Aug 2024
Reviewer:  Milan Lukas
Reviewer's report:
Dear authors,
thanks very much for revision manuscript sending to the next review. I have no more comments
or questions. I suggest that manuscript is fit for publication now.
Title: Comparative Real-world Outcomes between Ustekinumab, Infliximab, and Adalimumab
in Bio-naïve and Bio-experienced Crohn’s Disease Patients: A Retrospective Multicenter Study
Version: 4 Date: 10 Aug 2024
Reviewer:  Milan Lukas
Reviewer's report:
Dear authors,
thanks very much for revision manuscript sending to the next review. I have no more comments
or questions. I suggest that manuscript is fit for publication now.
Please review this paper.
user
Title: Comparative Real-world Outcomes between Ustekinumab, Infliximab, and Adalimumab
in Bio-naïve and Bio-experienced Crohn’s Disease Patients: A Retrospective Multicenter Study
Version: 4 Date: 10 Aug 2024
Reviewer:  Milan Lukas
Reviewer's report:
Dear authors,
thanks very much for revision manuscript sending to the next review. I have no more comments
or questions. I suggest that manuscript is fit for publication now.
assistant